Mohile Nimish A
Department of Neurology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA.
J Geriatr Oncol. 2016 Jan;7(1):1-6. doi: 10.1016/j.jgo.2015.12.001. Epub 2015 Dec 22.
Glioblastoma, a WHO grade IV astrocytoma, is the most common primary malignant brain tumor in adults. It is characterized by molecular heterogeneity and aggressive behavior. Glioblastoma is almost always incurable and most older patients survive less than 6 months. Supportive care with steroids and anti-epileptic drugs is critical to improving and maintain quality of life. Young age, good performance status and methylation of the methyl guanyl methyl transferase promoter are important positive prognostic factors. Several recent clinical trials suggest that there is a subset of the elderly with prolonged survival that is comparable to younger patients. Treatment of glioblastoma in older patients includes maximal safe resection followed by either radiation, chemotherapy or combined modality therapy. Recent advances suggest that some patients can avoid radiation entirely and be treated with chemotherapy alone. Decisions about therapy are individual and based on a patient's performance status, family support and molecular features. Future work needs to better determine the role for comprehensive geriatric assessments in this patient population to better identify patients who may most benefit from aggressive therapies.
胶质母细胞瘤是一种世界卫生组织IV级星形细胞瘤,是成人中最常见的原发性恶性脑肿瘤。它具有分子异质性和侵袭性。胶质母细胞瘤几乎总是无法治愈的,大多数老年患者存活期不到6个月。使用类固醇和抗癫痫药物的支持性护理对于改善和维持生活质量至关重要。年轻、良好的身体状况以及甲基鸟苷甲基转移酶启动子的甲基化是重要的积极预后因素。最近的几项临床试验表明,有一部分老年患者的生存期延长,与年轻患者相当。老年胶质母细胞瘤患者的治疗包括最大安全切除,随后进行放疗、化疗或联合治疗。最近的进展表明,一些患者可以完全避免放疗,仅接受化疗。治疗决策是个体化的,基于患者的身体状况、家庭支持和分子特征。未来的工作需要更好地确定综合老年评估在这一患者群体中的作用,以更好地识别可能从积极治疗中获益最大的患者。